[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-kidney-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-kidney-failure":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,75,109],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100619716","phase-1-a-clinical-trial-of-mk-2828-in-people-with-kidney-disease-mk-2828-006-100619716",false,"NCT07348237","A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)","An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of MK-2828 in Participants With Renal Impairment","The main inclusion criteria include but are not limited to the following:\n\n* Is in generally good health, with the exception of renal impairment participants. Participants with stable, chronic medical or psychiatric conditions may be included at the discretion of the investigator and the Sponsor.\n\nSevere Renal Impairment Participants:\n\n* Has an estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin), but is not on hemodialysis (HD)\n\nESRD on HD Participants:\n\n* Has ESRD maintained on stable outpatient regimen of intermittent high-flux HD at a healthcare center for \\> 3 months prior to study entry\n\nThe main exclusion criteria include but are not limited to the following:\n\nRenal Impairment Participants:\n\n* History of any illness, other than renal impairment, that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study.\n\nHealthy Matched Control Participants:\n\n* History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases. Participants with a remote history of uncomplicated medical events (eg, uncomplicated kidney stones, as defined as spontaneous passage and no recurrence in the last 5 years, or childhood asthma) may be enrolled in the study at the discretion of the investigator.",true,"ALL","24 Years","85 Years",{"count":21,"type":22},24,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.",[28,29,30],"Chronic Kidney Failure","End-Stage Renal Disease","Renal Impairment","RECRUITING","2026-06-01",{"date":34,"type":35},"2026-06-02","ACTUAL",{"date":37,"type":35},"2026-03-02",{"date":39,"type":22},"2026-07-20",{"name":41,"class":42},"Merck Sharp & Dohme LLC","INDUSTRY",3,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100591527","physical-impairments-in-children-with-chronic-renal-failure-100591527","NCT06981585","Physical Impairments in Children With Chronic Renal Failure","Comparison of Muscle Strength, Physical Activity, Sleep Quality and Quality of Life Between Children With Chronic Kidney Failure and Healthy Children","Inclusion Criteria: for Children and Adolescents with Chronic Kidney Failure\n\n* Being between the ages of 8-18\n* Being clinically stable for at least the last 3 weeks\n* Having the necessary cooperation for the measurements\n* Being willing to participate in the study\n\nInclusion Criteria for Healthy Children and Adolescents:\n\n* Being between the ages of 8-18,\n* Having the necessary cooperation for the measurements,\n* Being willing to participate in the research\n\nExclusion Criteria: for Children and Adolescents with Chronic Kidney Failure\n\n* Having any orthopedic, neurological, cardiovascular or psychological problems that may prevent measurements from being taken in the last 6 months\n* Being a smoker or having quit\n* Having had a kidney transplant.\n\nExclusion Criteria for Healthy Children and Adolescents:\n\n* Having a history of any orthopedic, neurological, cardiovascular or psychological problems that may prevent measurements from being taken in the last 6 months\n* Having any chronic disease\n* Being a smoker or having quit smoking","8 Years","18 Years",{"count":54,"type":22},25,"OBSERVATIONAL","When the literature is examined, it is seen that the extent to which cough strength, grip strength, physical activity level and quality of life levels are affected in children with chronic kidney failure compared to healthy children is not sufficiently clarified. For this reason, this study aimed to reveal impairments in grip strength, cough strength, physical activity, sleep quality or quality of life in children with chronic renal failure compared to healthy children.",[28,58],"Chronic Kidney Diseases",[28,60,61,62,63],"Muscle Strength","Physical Activity","Sleep Quality","Quality of Life","2025-08-26",{"date":66,"type":35},"2025-08-28",{"date":68,"type":35},"2025-08-01",{"date":70,"type":22},"2027-03-01",{"name":72,"class":73},"Izmir Democracy University","OTHER",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":99,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":43},"100584264","systemic-activation-of-inflammasomes-and-frailty-in-older-candidates-to-kidney-transplantation-100584264","NCT06887075","Systemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation","INTRA","* Inclusion criteria:\n\n  * Age ≥ 70\n  * Patient candidate to kidney transplantation (during assessment for inscription on the waiting-list, or during waiting time after effective inscription), without absolute contraindication\n  * Free, informed and written consent signed by the participant and the investigator (at the latest, on the day of inclusion and before any examination required by the research).\n  * Person affiliated or beneficiary of a social security scheme\n* Exclusion criteria:\n\n  * Inclusion in an industrial study refusing co-inclusion in our study\n  * Person under guardianship, assisted decision-making or under temporary guardianship","70 Years",{"count":84,"type":22},60,[86],"NA","Kidney transplantation (KT) benefit-risk ratio assessment is a challenge in a growing population of older patients with end-stage kidney disease. A pre-KT frailty phenotype has been found predictive of post-KT complications, but biological mechanisms of frailty are poorly known is these patients. Frailty is associated with chronic low-grade inflammation in the older general population, possibly through the inflammasome pathway. Our main objective is to assess if systemic activation of inflammasomes is associated with frailty in older candidates to KT.",[28,89,90,91],"Frailty","Aging","Inflammation",[93,94,95,96,97,98,89],"Older persons","End-stage kidney disease","Kidney transplantation","Immune aging","Chronic low-grade inflammation","Inflammasomes","NOT_YET_RECRUITING","2025-03-14",{"date":102,"type":35},"2025-03-20",{"date":104,"type":22},"2025-04-15",{"date":106,"type":22},"2027-02-15",{"name":108,"class":73},"University Hospital, Bordeaux",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":74},"100482502","phase-3-belatacept-as-a-replacement-for-cnis-3-to-12-months-post-transplantation-in-patients-with-early-graft-dysfunction-100482502","NCT05562869","Belatacept as a Replacement for CNIs 3 to 12 Months Post-transplantation in Patients With Early Graft Dysfunction","BELASBRIDGE","Inclusion Criteria:\n\n* adult older than 18 years old.\n* transplantation of a deceased or living donor kidney (non-human leukocyte antigen(HLA)-identical) with blood type (ABO) compatibility\n* no contraindication to the protocol graft biopsy (10 weeks post transplant)\n* treatment by CNI \u002F MPA +\u002F- prednisone\n* renal function estimated by creatinine clearance according to CKD-EPI \\\u003C30 ml \u002F min \u002F 1.73m2.\n* having no difficulty in understanding and communicating with the investigator and his representatives.\n* Agreeing to give informed written consent\n* benefiting from a Social Security policy.\n* results of the 10-week post-transplant renal biopsy finding no rejection or BK virus (member of the polyomavirus family) nephropathy, no recurrence, no thrombotic microangiopathy, no cortical necrosis.\n* Seropositivity for Epstein-Barr virus (EBV)\n* negative pregnancy test and agreement on the use of effective contraception throughout the study\n\nExclusion Criteria:\n\n* Presence of Donor Specific Antibody during kidney transplant or appeared at 3 months post-transplantation.\n* seropositivity for HIV\n* another history of other solid organ transplants (outside the kidney)\n* primary non-function (persistence of a need for dialysis at 3 months post-transplantation)\n* participation in progress to another interventional clinical study\n* any clinical condition that the investigator considers incompatible with the course of the study.\n* contraindication to belatacept and Tacrolimus\n* Pregnant or breastfeeding woman\n* Inability of the patient to comply with study procedures\n* Person placed under guardianship or curatorship, under safeguard of justice","99 Years",{"count":118,"type":22},30,[120],"PHASE3","Calcineurin inhibitors (CNI) remain the standard treatment in renal transplantation to prevent rejection. Currently the main limitation of kidney transplantation is the occurrence of chronic graft dysfunction due to the CNI nephrotoxicity. Thus, strategies to minimize or stop CNI have been developed as belatacept, a fusion protein (CTLA4-Ig) blocking the ligand of the main CD28 costimulatory molecule. In the original phase III trial, used de novo in combination with MMF (without CNI) belatacept allowed to obtain a better renal function as soon as 1 year and a better graft and patient survival after 7 years. Despite these excellent results, belatacept has not become the gold standard due to a higher incidence of early rejection. In addition, belatacept is not covered by the french social security policy, because benefits are considered insufficient with respect to the cost. Patients with poor early graft function are a preferred indication of belatacept. It is then used instead of CNI at 3 months post-transplant allowing to improve kidney function without over-risk of rejection. Currently after conversion, belatacept is maintained indefinitely due to the supposed CNI chronic nephrotoxicity. However this one is more and more questionable. Thus, the investigators assume that in patients with poor function at 3 months posttransplantation the belatacept's benefit could be obtained by a transient replacement of CNI by belatacept from 3 to 12 months post-transplantation. It is the feasibility of this strategy and its medico-economic impact that the investigators wish to study.",[28],"2024-05-07",{"date":125,"type":35},"2024-05-09",{"date":127,"type":35},"2024-05-03",{"date":129,"type":22},"2027-05-03",{"name":131,"class":73},"Nantes University Hospital"]